Sir John Bell

News

Failure to strike a Brexit deal allowing alignment with the European Medicines Agency would be ‘catastrophic’ for the UK life sciences sector.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.